Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.

Literature DB >> 10577975

Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.

G Harriman¹, L K Harper, T F Schaible.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 1999 PMID： 10577975 PMCID： PMC1766581 DOI： 10.1136/ard.58.2008.i61

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

8 in total

1. Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors: D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal: N Engl J Med Date: 1999-05-06 Impact factor: 91.245

2. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

Authors: G D'haens; S Van Deventer; R Van Hogezand; D Chalmers; C Kothe; F Baert; T Braakman; T Schaible; K Geboes; P Rutgeerts
Journal: Gastroenterology Date: 1999-05 Impact factor: 22.682

3. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245

4. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Authors: F J Baert; G R D'Haens; M Peeters; M I Hiele; T F Schaible; D Shealy; K Geboes; P J Rutgeerts
Journal: Gastroenterology Date: 1999-01 Impact factor: 22.682

5. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

Authors: B J Scallon; M A Moore; H Trinh; D M Knight; J Ghrayeb
Journal: Cytokine Date: 1995-04 Impact factor: 3.861

6. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

Authors: D M Knight; H Trinh; J Le; S Siegel; D Shealy; M McDonough; B Scallon; M A Moore; J Vilcek; P Daddona
Journal: Mol Immunol Date: 1993-11 Impact factor: 4.407

7. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors: M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal: Lancet Date: 1994-10-22 Impact factor: 79.321

8. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors: R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal: Arthritis Rheum Date: 1998-09

8 in total

19 in total

Review 1. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; C E Antoni; J W J Bijlsma; G R Burmester; B Cronstein; E C Keystone; A Kavanaugh; L Klareskog
Journal: Ann Rheum Dis Date: 2002-11 Impact factor: 19.103

Review 2. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal: Ann Rheum Dis Date: 2003-11 Impact factor: 19.103

3. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal: Ann Rheum Dis Date: 2006-11 Impact factor: 19.103

Review 4. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal: Ann Rheum Dis Date: 2007-11 Impact factor: 19.103

Review 5. Infliximab: a review of its use in the management of rheumatoid arthritis.

Authors: A Markham; H M Lamb
Journal: Drugs Date: 2000-06 Impact factor: 9.546

Review 6. Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients.

Authors: Paul Ornetti; Hélène Chevillotte; Amal Zerrak; Jean Francis Maillefert
Journal: Drugs Aging Date: 2006 Impact factor: 3.923

Review 7. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal: Ann Rheum Dis Date: 2004-11 Impact factor: 19.103